Revenues sag at Sagentia as medical project suspended
The research and development consultancy, Sagentia, has issued a warning on 2012 revenues after a big project with a north American medical start-up was suspended.
The research and development consultancy, Sagentia, has issued a warning on 2012 revenues after a big project with a north American medical start-up was suspended.
Sagentia says the suspension will see revenues in the first half of 2012 coming in lower than the second six months of 2011. The group also expects revenues for full year 2012 to be below 2011.
The group's update maintains: "Actions have been taken to mitigate this event and these have been effective in enhancing operating margins. As a result for the full year, while revenue will be lower than last year, profit is anticipated to be in line with the Board's expectations."
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Investors are clearly rattled, the stock had fallen 11% by 10:18.
BS
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
Starling Bank to scrap 3.25% interest rate from popular current account within days
Starling is to remove the generous 3.25% it pays on current accounts from next week – what does this mean for customers and should you move?
By Katie Williams Published
-
Top 20 UK areas where house prices have ballooned in last 25 years
Some parts of the UK have seen house prices grow by 652% since the turn of the millennium
By Daniel Hilton Published